tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Thomas Shrader, 227 are a BUY (93.42%), 16 are a HOLD (6.58%).
Analyst Thomas Shrader, currently employed at BTIG, carries an average stock price target met ratio of 46.27% that have a potential upside of 42.8% achieved within 241 days.
Thomas Shrader’s has documented 460 price targets and ratings displayed on 51 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ABOS, Acumen Pharmaceuticals.
Analyst best performing recommendations are on EIDX (EIDOS THERAPEUTICS).
The best stock recommendation documented was for VRNA (VERONA PHARMA PLC ADR) at 12/20/2022. The price target of $26 was fulfilled within 10 days with a profit of $7.41 (39.86%) receiving and performance score of 39.86.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 13-Apr-2020
$120
$47.56 (65.65%)
$120
6 days ago
(10-Sep-2026)
32/40 (80%)
$47.5 (65.52%)
381
Buy Since 19-Feb-2020
$110
$37.56 (51.85%)
$96
15 days ago
(01-Sep-2026)
18/23 (78.26%)
$33.43 (43.66%)
610
Buy Since 22-Jul-2019
$111
$38.56 (53.23%)
$94
1 months 4 days ago
(12-Aug-2026)
16/18 (88.89%)
$27.16 (32.40%)
200
Buy Since 24-Jun-2024
$107
$34.56 (47.71%)
$102
1 months 4 days ago
(12-Aug-2026)
6/9 (66.67%)
$23.16 (27.62%)
196
Buy Since 06-Jan-2026
$97
$24.56 (33.90%)
$98
1 months 5 days ago
(11-Aug-2026)
0/4 (0%)
$13.3 (15.89%)
Which stock is Thomas Shrader most bullish on?
Which stock is Thomas Shrader most reserved on?
What Year was the first public recommendation made by Thomas Shrader?
